Interestingly, the therapeutic potential of recombinant and vector delivered HGF for ALS is being tested in clinical trials (Sufit et al., 2002; Sun et al., 2002; Warita et al., 2019) that, thus far, have demonstrated safety and tolerability. Here, HGF is linked to amyotrophic lateral sclerosis.